Pfizer’s New Head Of Orphan And Genetic Diseases Looks To Shake Up The Big Pharma Problem-Solving Model
This article was originally published in The Pink Sheet Daily
Pfizer’s new head of orphan and genetic diseases, Kevin Lee, aims to build a capability within the Big Pharma that is specifically focused on rare diseases, employing a “partner by first intent” problem solving philosophy that reaches across other internal units and across the scientific community.
You may also be interested in...
Though the tracks and sessions are still named largely for organs and other phenotypic descriptions of cancer, the notion of basing treatments on the molecular drivers of a tumor alone is pervasive at this year’s meeting of the American Society of Clinical Oncology, June 1-5 in Chicago.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.